Statins and the risk of dementia

H. Jick, G. L. Zornberg, S. S. Jick, Sudha Seshadri, D. A. Drachman

Research output: Contribution to journalArticle

1471 Citations (Scopus)

Abstract

Background: Dementia affects an estimated 10% of the population older than 65 years. Because vascular and lipid-related mechanisms are thought to have a role in the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of the potential effect of HMGCoA (3 hydroxy-3methylglutaryl-coenzyme A) reductase inhibitors (statins) and other lipid-lowering agents on dementia. Methods: We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case. Findings: The study encompassed 284 cases with dementia and 1 080 controls. Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for age, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% Cl 0.45-1.14]), or treated with non-statin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002). Interpretation: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to non-statin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.

Original languageEnglish (US)
Pages (from-to)1627-1631
Number of pages5
JournalLancet
Volume356
Issue number9242
DOIs
StatePublished - Nov 11 2000
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Dementia
Hyperlipidemias
Lipids
Alzheimer Disease
Population
Vascular Dementia
Coenzyme A
Brain Ischemia
General Practice
Blood Vessels
Epidemiologic Studies
Coronary Artery Disease
Oxidoreductases
Body Mass Index
Age Groups
Smoking
Odds Ratio
Databases
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., & Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356(9242), 1627-1631. https://doi.org/10.1016/S0140-6736(00)03155-X

Statins and the risk of dementia. / Jick, H.; Zornberg, G. L.; Jick, S. S.; Seshadri, Sudha; Drachman, D. A.

In: Lancet, Vol. 356, No. 9242, 11.11.2000, p. 1627-1631.

Research output: Contribution to journalArticle

Jick, H, Zornberg, GL, Jick, SS, Seshadri, S & Drachman, DA 2000, 'Statins and the risk of dementia', Lancet, vol. 356, no. 9242, pp. 1627-1631. https://doi.org/10.1016/S0140-6736(00)03155-X
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11;356(9242):1627-1631. https://doi.org/10.1016/S0140-6736(00)03155-X
Jick, H. ; Zornberg, G. L. ; Jick, S. S. ; Seshadri, Sudha ; Drachman, D. A. / Statins and the risk of dementia. In: Lancet. 2000 ; Vol. 356, No. 9242. pp. 1627-1631.
@article{f9b305b72e1648c190338a5b83a73f90,
title = "Statins and the risk of dementia",
abstract = "Background: Dementia affects an estimated 10{\%} of the population older than 65 years. Because vascular and lipid-related mechanisms are thought to have a role in the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of the potential effect of HMGCoA (3 hydroxy-3methylglutaryl-coenzyme A) reductase inhibitors (statins) and other lipid-lowering agents on dementia. Methods: We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case. Findings: The study encompassed 284 cases with dementia and 1 080 controls. Among controls 13{\%} had untreated hyperlipidaemia, 11{\%} were prescribed statins, 7{\%} other LLAs, and 69{\%} had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for age, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95{\%} Cl 0.45-1.14]), or treated with non-statin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002). Interpretation: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to non-statin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.",
author = "H. Jick and Zornberg, {G. L.} and Jick, {S. S.} and Sudha Seshadri and Drachman, {D. A.}",
year = "2000",
month = "11",
day = "11",
doi = "10.1016/S0140-6736(00)03155-X",
language = "English (US)",
volume = "356",
pages = "1627--1631",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9242",

}

TY - JOUR

T1 - Statins and the risk of dementia

AU - Jick, H.

AU - Zornberg, G. L.

AU - Jick, S. S.

AU - Seshadri, Sudha

AU - Drachman, D. A.

PY - 2000/11/11

Y1 - 2000/11/11

N2 - Background: Dementia affects an estimated 10% of the population older than 65 years. Because vascular and lipid-related mechanisms are thought to have a role in the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of the potential effect of HMGCoA (3 hydroxy-3methylglutaryl-coenzyme A) reductase inhibitors (statins) and other lipid-lowering agents on dementia. Methods: We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case. Findings: The study encompassed 284 cases with dementia and 1 080 controls. Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for age, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% Cl 0.45-1.14]), or treated with non-statin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002). Interpretation: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to non-statin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.

AB - Background: Dementia affects an estimated 10% of the population older than 65 years. Because vascular and lipid-related mechanisms are thought to have a role in the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of the potential effect of HMGCoA (3 hydroxy-3methylglutaryl-coenzyme A) reductase inhibitors (statins) and other lipid-lowering agents on dementia. Methods: We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case. Findings: The study encompassed 284 cases with dementia and 1 080 controls. Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for age, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% Cl 0.45-1.14]), or treated with non-statin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002). Interpretation: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to non-statin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.

UR - http://www.scopus.com/inward/record.url?scp=0034638746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034638746&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)03155-X

DO - 10.1016/S0140-6736(00)03155-X

M3 - Article

C2 - 11089820

AN - SCOPUS:0034638746

VL - 356

SP - 1627

EP - 1631

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9242

ER -